{
    "ticker": "MTEX",
    "name": "Molecular Templates, Inc.",
    "description": "Molecular Templates, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies for the treatment of cancer. Founded in 2012 and headquartered in Austin, Texas, MTEX leverages its proprietary platform, known as the Engineered Toxin Body (ETB), to design and produce targeted protein therapeutics that can selectively kill cancer cells while minimizing damage to healthy tissues. The company's lead product candidate, MT-3724, is in clinical trials for the treatment of patients with non-Hodgkin lymphoma. Molecular Templates is committed to advancing its pipeline of ETB candidates through rigorous research and clinical evaluation, aiming to address unmet medical needs in oncology. The firm collaborates with leading researchers and institutions to further enhance its innovative approaches to cancer treatment. With a strong focus on advancing science and improving patient outcomes, Molecular Templates is at the forefront of the biopharmaceutical industry, striving to make significant contributions to cancer care.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Austin, Texas, USA",
    "founded": "2012",
    "website": "https://www.moleculartemplates.com",
    "ceo": "Eric Poma",
    "social_media": {
        "twitter": "https://twitter.com/MolecularTmpl",
        "linkedin": "https://www.linkedin.com/company/molecular-templates/"
    },
    "investor_relations": "https://investors.moleculartemplates.com",
    "key_executives": [
        {
            "name": "Eric Poma",
            "position": "CEO"
        },
        {
            "name": "Michael Kauffman",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Oncology Therapies",
            "products": [
                "MT-3724"
            ]
        }
    ],
    "seo": {
        "meta_title": "Molecular Templates, Inc. | Innovative Cancer Therapies",
        "meta_description": "Explore Molecular Templates, Inc., a leader in cancer treatment innovation, developing targeted protein therapeutics to improve patient outcomes.",
        "keywords": [
            "Molecular Templates",
            "Cancer Therapy",
            "Biopharmaceuticals",
            "ETB",
            "MT-3724"
        ]
    },
    "faq": [
        {
            "question": "What is Molecular Templates known for?",
            "answer": "Molecular Templates is known for its Engineered Toxin Body (ETB) platform and innovative cancer therapies."
        },
        {
            "question": "Who is the CEO of Molecular Templates?",
            "answer": "Eric Poma is the CEO of Molecular Templates, Inc."
        },
        {
            "question": "Where is Molecular Templates headquartered?",
            "answer": "Molecular Templates is headquartered in Austin, Texas, USA."
        },
        {
            "question": "What is the lead product candidate of Molecular Templates?",
            "answer": "The lead product candidate is MT-3724, which is in clinical trials for non-Hodgkin lymphoma."
        },
        {
            "question": "When was Molecular Templates founded?",
            "answer": "Molecular Templates was founded in 2012."
        }
    ],
    "competitors": [
        "CRSP",
        "BMRN",
        "RGEN",
        "EDIT"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "REGN",
        "VRTX"
    ]
}